Companies Complement Therapeutics

Turning powerful new Complement System insights into innovative treatments


Geographic atrophy (late dry age-related macular degeneration) is a chronic eye condition that affects millions – and for which there is currently no available treatment. The disease is related to Complement System disorders.

Through an extensive programme of translational research we have gained powerful new insights into the ways the Complement System works and how it is dysregulated in age-related macular degeneration. We are now using these insights to develop a portfolio of treatments for Complement-related diseases including age-related macular degeneration, each with a high unmet clinical need.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More